Cancer Research Cell Death Mechanisms and Cancer Therapy Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graff, J. R.
Right arrow Articles by Thornton, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Graff, J. R.
Right arrow Articles by Thornton, D.
[Cancer Research 65, 7462-7469, August 15, 2005]
© 2005 American Association for Cancer Research

Experimental Therapeutics, Molecular Targets, and Chemical Biology

The Protein Kinase Cß–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts

Jeremy R. Graff, Ann M. McNulty, Kimberly Ross Hanna, Bruce W. Konicek, Rebecca L. Lynch, Spring N. Bailey, Crystal Banks, Andrew Capen, Robin Goode, Jason E. Lewis, Lillian Sams, Karen L. Huss, Robert M. Campbell, Philip W. Iversen, Blake Lee Neubauer, Thomas J. Brown, Luna Musib, Sandaruwan Geeganage and Donald Thornton

Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana

Requests for reprints: Jeremy R. Graff, Principal Research Scientist, Cancer Growth and Translational Genetics, Oncology Division, Lilly Research Labs, Lilly Corporate Center, DC0546, Indianapolis, IN 46285. Phone: 317-277-0220; Fax: 317-277-3652; E-mail: graff_jeremy{at}lilly.com.

Activation of protein kinase Cß (PKCß) has been repeatedly implicated in tumor-induced angiogenesis. The PKCß-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses angiogenesis and was advanced for clinical development based upon this antiangiogenic activity. Activation of PKCß has now also been implicated in tumor cell proliferation, apoptosis, and tumor invasiveness. Herein, we show that Enzastaurin has a direct effect on human tumor cells, inducing apoptosis and suppressing the proliferation of cultured tumor cells. Enzastaurin treatment also suppresses the phosphorylation of GSK3ßser9, ribosomal protein S6S240/244, and AKTThr308. Oral dosing with Enzastaurin to yield plasma concentrations similar to those achieved in clinical trials significantly suppresses the growth of human glioblastoma and colon carcinoma xenografts. As in cultured tumor cells, Enzastaurin treatment suppresses the phosphorylation of GSK3ß in these xenograft tumor tissues. Enzastaurin treatment also suppresses GSK3ß phosphorylation to a similar extent in peripheral blood mononuclear cells (PBMCs) from these treated mice. These data show that Enzastaurin has a direct antitumor effect and that Enzastaurin treatment suppresses GSK3ß phosphorylation in both tumor tissue and in PBMCs, suggesting that GSK3ß phosphorylation may serve as a reliable pharmacodynamic marker for Enzastaurin activity. With previously published reports, these data support the notion that Enzastaurin suppresses tumor growth through multiple mechanisms: direct suppression of tumor cell proliferation and the induction of tumor cell death coupled to the indirect effect of suppressing tumor-induced angiogenesis.




This article has been cited by other articles:


Home page
 Ann OncolHome page
B. Glimelius, K.L. Spindler, J.-E. Frodin, A. Berglund, P. Bystrom, C. Qvortrup, A. Jakobsen, and P. Pfeiffer
Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study
Ann. Onc., November 13, 2009; (2009) mdp526v1.
[Full Text] [PDF]

Home page
 Ann OncolHome page
B. Glimelius, M. Lahn, S. Gawande, A. Cleverly, C. Darstein, L. Musib, Y. Liu, K. L. Spindler, J.-E. Frodin, A. Berglund, et al.
A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer
Ann. Onc., November 9, 2009; (2009) mdp521v1.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
N. Normanno, A. Morabito, A. De Luca, M. C. Piccirillo, M. Gallo, M. R Maiello, and F. Perrone
Target-based therapies in breast cancer: current status and future perspectives
Endocr. Relat. Cancer, September 1, 2009; 16(3): 675 - 702.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A.-R. Hanauske, M. Lahn, L. C. Musib, K. Weigang-Kohler, E. Yilmaz, T. Graefe, B. Kuenen, D. Thornton, P. McNealy, and G. Giaccone
Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer
Ann. Onc., September 1, 2009; 20(9): 1565 - 1575.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. M. Schrage, I. H. Briaire-de Bruijn, N. F.C.C. de Miranda, J. van Oosterwijk, A. H.M. Taminiau, T. van Wezel, P. C.W. Hogendoorn, and J. V.M.G. Bovee
Kinome Profiling of Chondrosarcoma Reveals Src-Pathway Activity and Dasatinib as Option for Treatment
Cancer Res., August 1, 2009; 69(15): 6216 - 6222.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
J. Bodo, L. Durkin, and E. D. Hsi
Quantitative In Situ Detection of Phosphoproteins in Fixed Tissues Using Quantum Dot Technology
J. Histochem. Cytochem., July 1, 2009; 57(7): 701 - 708.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
W. Jian, H. Yamashita, J. M. Levitt, S. P. Lerner, and G. Sonpavde
Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine
Mol. Cancer Ther., July 1, 2009; 8(7): 1772 - 1778.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Zhang, M. Sattler, G. Tonon, C. Grabher, S. Lababidi, A. Zimmerhackl, M. S. Raab, S. Vallet, Y. Zhou, M.-A. Cartron, et al.
Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1{alpha}-Dependent Pathway in Multiple Myeloma
Cancer Res., June 15, 2009; 69(12): 5082 - 5090.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. R. Graff, B. W. Konicek, R. L. Lynch, C. A. Dumstorf, M. S. Dowless, A. M. McNulty, S. H. Parsons, L. H. Brail, B. M. Colligan, J. W. Koop, et al.
eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival
Cancer Res., May 1, 2009; 69(9): 3866 - 3873.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Delmonte, M. Ghielmini, and C. Sessa
Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin's Lymphomas
Oncologist, May 1, 2009; 14(5): 511 - 525.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Holler, J. D. Pinon, U. Denk, C. Heyder, S. Hofbauer, R. Greil, and A. Egle
PKC{beta} is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKC{beta} as a therapeutic target in chronic lymphocytic leukemia
Blood, March 19, 2009; 113(12): 2791 - 2794.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. P. Fields, S. R. Calcagno, M. Krishna, S. Rak, M. Leitges, and N. R. Murray
Protein Kinase C{beta} Is an Effective Target for Chemoprevention of Colon Cancer
Cancer Res., February 15, 2009; 69(4): 1643 - 1650.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. S. Raab, I. Breitkreutz, G. Tonon, J. Zhang, P. J. Hayden, T. Nguyen, J. H. Fruehauf, B. K. Lin, D. Chauhan, T. Hideshima, et al.
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling
Blood, February 12, 2009; 113(7): 1513 - 1521.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. R. Murray, J. Weems, U. Braun, M. Leitges, and A. P. Fields
Protein Kinase C {beta}II and PKC{iota}/{lambda}: Collaborating Partners in Colon Cancer Promotion and Progression
Cancer Res., January 15, 2009; 69(2): 656 - 662.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Kotliarova, S. Pastorino, L. C. Kovell, Y. Kotliarov, H. Song, W. Zhang, R. Bailey, D. Maric, J. C. Zenklusen, J. Lee, et al.
Glycogen Synthase Kinase-3 Inhibition Induces Glioma Cell Death through c-MYC, Nuclear Factor-{kappa}B, and Glucose Regulation
Cancer Res., August 15, 2008; 68(16): 6643 - 6651.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Kim, Y.-L. Choi, A. Vallentin, B. S. Hunrichs, M. K. Hellerstein, D. M. Peehl, and D. Mochly-Rosen
Centrosomal PKC{beta}II and Pericentrin Are Critical for Human Prostate Cancer Growth and Angiogenesis
Cancer Res., August 15, 2008; 68(16): 6831 - 6839.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
F. Morgillo, E. Martinelli, T. Troiani, G. Laus, S. Pepe, C. Gridelli, and F. Ciardiello
Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase C{beta} inhibitor, in non-small cell lung cancer cells
Mol. Cancer Ther., June 1, 2008; 7(6): 1698 - 1707.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K.-W. Lee, S. G. Kim, H.-P. Kim, E. Kwon, J. You, H.-J. Choi, J.-H. Park, B.-C. Kang, S.-A. Im, T.-Y. Kim, et al.
Enzastaurin, a Protein Kinase C{beta} Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells
Cancer Res., March 15, 2008; 68(6): 1916 - 1926.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Y. Oh, R. S. Herbst, H. Burris, A. Cleverly, L. Musib, M. Lahn, and G. Bepler
Enzastaurin, an Oral Serine/Threonine Kinase Inhibitor, As Second- or Third-Line Therapy of Non-Small-Cell Lung Cancer
J. Clin. Oncol., March 1, 2008; 26(7): 1135 - 1141.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Morschhauser, J. F. Seymour, H. C. Kluin-Nelemans, A. Grigg, M. Wolf, M. Pfreundschuh, H. Tilly, J. Raemaekers, M. B. van 't Veer, N. Milpied, et al.
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
Ann. Onc., February 1, 2008; 19(2): 247 - 253.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
S. O'Brien
New Agents in the Treatment of CLL
Hematology, January 1, 2008; 2008(1): 457 - 464.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. C. Spalding, R. Watson, M. E. Davis, A. C. Kim, T. S. Lawrence, and E. Ben-Josef
Inhibition of Protein Kinase C{beta} by Enzastaurin Enhances Radiation Cytotoxicity in Pancreatic Cancer
Clin. Cancer Res., November 15, 2007; 13(22): 6827 - 6833.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
P. A. Welch, V. P. Sinha, A. L. Cleverly, C. Darstein, S. D. Flanagan, and L. C. Musib
Safety, Tolerability, QTc Evaluation, and Pharmacokinetics of Single and Multiple Doses of Enzastaurin HCl (LY317615), a Protein Kinase C-{beta} Inhibitor, in Healthy Subjects
J. Clin. Pharmacol., September 1, 2007; 47(9): 1138 - 1151.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Rademaker-Lakhai, L. V. Beerepoot, N. Mehra, S. A. Radema, R. van Maanen, J. S. Vermaat, E. O. Witteveen, C. M. Visseren-Grul, L. Musib, N. Enas, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C {beta}-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer
Clin. Cancer Res., August 1, 2007; 13(15): 4474 - 4481.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. S. Herbst, Y. Oh, A. Wagle, and M. Lahn
Enzastaurin, a Protein Kinase C{beta} Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer
Clin. Cancer Res., August 1, 2007; 13(15): 4641s - 4646s.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. M.P. Omuro, S. Faivre, and E. Raymond
Lessons learned in the development of targeted therapy for malignant gliomas
Mol. Cancer Ther., July 1, 2007; 6(7): 1909 - 1919.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Younes, X. Leleu, E. Hatjiharissi, A.-S. Moreau, T. Hideshima, P. Richardson, K. C. Anderson, and I. M. Ghobrial
Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple Myeloma
Clin. Cancer Res., July 1, 2007; 13(13): 3771 - 3775.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. W. Robey, S. Shukla, K. Steadman, T. Obrzut, E. M. Finley, S. V. Ambudkar, and S. E. Bates
Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure
Mol. Cancer Ther., June 1, 2007; 6(6): 1877 - 1885.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A.-S. Moreau, X. Jia, H. T. Ngo, X. Leleu, G. O'Sullivan, Y. Alsayed, A. Leontovich, K. Podar, J. Kutok, J. Daley, et al.
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia
Blood, June 1, 2007; 109(11): 4964 - 4972.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Robertson, B. S. Kahl, J. M. Vose, S. de Vos, M. Laughlin, P. J. Flynn, K. Rowland, J. C. Cruz, S. L. Goldberg, L. Musib, et al.
Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
J. Clin. Oncol., May 1, 2007; 25(13): 1741 - 1746.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Podar, M. S. Raab, J. Zhang, D. McMillin, I. Breitkreutz, Y.-T. Tai, B. K. Lin, N. Munshi, T. Hideshima, D. Chauhan, et al.
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)
Blood, February 15, 2007; 109(4): 1669 - 1677.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. I. Fomchenko and E. C. Holland
Mouse models of brain tumors and their applications in preclinical trials.
Clin. Cancer Res., September 15, 2006; 12(18): 5288 - 5297.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Carducci, L. Musib, M. S. Kies, R. Pili, M. Truong, J. R. Brahmer, P. Cole, R. Sullivan, J. Riddle, J. Schmidt, et al.
Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer
J. Clin. Oncol., September 1, 2006; 24(25): 4092 - 4099.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. A. Rizvi, K. Ghias, K. M. Davies, C. Ma, F. Weinberg, H. G. Munshi, N. L. Krett, and S. T. Rosen
Enzastaurin (LY317615), a protein kinase C{beta} inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.
Mol. Cancer Ther., July 1, 2006; 5(7): 1783 - 1789.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
M. F. McCarty and K. I. Block
Toward a Core Nutraceutical Program for Cancer Management
Integr Cancer Ther, June 1, 2006; 5(2): 150 - 171.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
L. J. Green, P. Marder, C. Ray, C. A. Cook, S. Jaken, L. C. Musib, R. S. Herbst, M. Carducci, C. D. Britten, M. Basche, et al.
Development and Validation of a Drug Activity Biomarker that Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C-{beta} Inhibitor.
Clin. Cancer Res., June 1, 2006; 12(11): 3408 - 3415.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.